Ascentage Pharma Group (AAPG)

Executive Summary

Ascentage Pharma Group (HKEX: AAPG) is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to developing novel therapies that modulate apoptosis and autophagy pathways. The company's pipeline includes several oncology candidates targeting key proteins such as IAP, MDM2-p53, and Bcl-2/Bcl-xL, with lead assets in late-stage clinical development globally. Its most advanced program, olverembatinib (a BCR-ABL inhibitor), has received conditional approval in China for chronic myeloid leukemia (CML) and is under further development for gastrointestinal stromal tumors (GIST) and Ph+ acute lymphoblastic leukemia. Other notable candidates include the Bcl-2 inhibitor APG-2575, which is in Phase 3 studies for chronic lymphocytic leukemia (CLL), and the MDM2-p53 inhibitor APG-115, in Phase 2 for various solid tumors. Beyond oncology, the company is progressing a functional cure for chronic hepatitis B. With a strong focus on differentiated targets and an integrated discovery-to-manufacturing platform, Ascentage is positioned to address significant unmet medical needs in cancer and infectious diseases.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 data readout for APG-2575 in CLL75% success
• Q1 2026NDA submission for olverembatinib in GIST80% success
• TBDPartnering or licensing deal for pipeline assets50% success